XML 48 R39.htm IDEA: XBRL DOCUMENT
v3.22.1

Reportable Segment Information (Tables) | 6 Months Ended
--- | ---
Mar. 31, 2022
Segment Reporting [Abstract] |
Summary of Financial Information for Each Reportable Segment | The following table presents various financial information for each reportable segment for the three and six months ended March 31, 2022 and 2021.
| Three months ended |  |  | Six months ended |
| March 31 |  |  | March 31 |
(In millions - unaudited) | 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
SALES |  |  |  |  |  |  |  |  |  |  |
Life Sciences | $ | 204 |  |  | $ | 185 |  |  | $ | 374 |  |  | $ | 355 |
Personal Care |  | 172 |  |  |  | 137 |  |  |  | 318 |  |  |  | 262 |
Specialty Additives |  | 182 |  |  |  | 158 |  |  |  | 338 |  |  |  | 305 |
Intermediates |  | 66 |  |  |  | 37 |  |  |  | 119 |  |  |  | 69 |
Intersegment sales (a) |  | (20 | ) |  |  | (8 | ) |  |  | (34 | ) |  |  | (14 | )
| $ | 604 |  |  | $ | 509 |  |  | $ | 1,115 |  |  | $ | 977 |
OPERATING INCOME (LOSS) |  |  |  |  |  |  |  |  |  |  |
Life Sciences | $ | 43 |  |  | $ | 35 |  |  | $ | 64 |  |  | $ | 64 |
Personal Care |  | 28 |  |  |  | 19 |  |  |  | 42 |  |  |  | 33 |
Specialty Additives (b) |  | 26 |  |  |  | 19 |  |  |  | 44 |  |  |  | 21 |
Intermediates |  | 27 |  |  |  | 3 |  |  |  | 42 |  |  |  | 5 |
Unallocated and other |  | (31 | ) |  |  | (28 | ) |  |  | (57 | ) |  |  | (57 | )
| $ | 93 |  |  | $ | 48 |  |  | $ | 135 |  |  | $ | 66 |
DEPRECIATION EXPENSE |  |  |  |  |  |  |  |  |  |  |
Life Sciences | $ | 8 |  |  | $ | 8 |  |  | $ | 16 |  |  | $ | 17 |
Personal Care |  | 9 |  |  |  | 9 |  |  |  | 18 |  |  |  | 19 |
Specialty Additives |  | 17 |  |  |  | 16 |  |  |  | 33 |  |  |  | 33 |
Intermediates |  | 3 |  |  |  | 4 |  |  |  | 7 |  |  |  | 6 |
| $ | 37 |  |  | $ | 37 |  |  | $ | 74 |  |  | $ | 75 |
AMORTIZATION EXPENSE |  |  |  |  |  |  |  |  |  |  |
Life Sciences | $ | 7 |  |  | $ | 7 |  |  | $ | 14 |  |  | $ | 14 |
Personal Care |  | 12 |  |  |  | 10 |  |  |  | 24 |  |  |  | 19 |
Specialty Additives |  | 5 |  |  |  | 5 |  |  |  | 9 |  |  |  | 9 |
Intermediates |  | — |  |  |  | — |  |  |  | — |  |  |  | 1 |
| $ | 24 |  |  | $ | 22 |  |  | $ | 47 |  |  | $ | 43 |
EBITDA (c) |  |  |  |  |  |  |  |  |  |  |
Life Sciences | $ | 58 |  |  | $ | 50 |  |  | $ | 94 |  |  | $ | 95 |
Personal Care |  | 49 |  |  |  | 38 |  |  |  | 84 |  |  |  | 71 |
Specialty Additives |  | 48 |  |  |  | 40 |  |  |  | 86 |  |  |  | 63 |
Intermediates |  | 30 |  |  |  | 7 |  |  |  | 49 |  |  |  | 12 |
Unallocated and other |  | (31 | ) |  |  | (28 | ) |  |  | (57 | ) |  |  | (57 | )
| $ | 154 |  |  | $ | 107 |  |  | $ | 256 |  |  | $ | 184 |
| March 31 |  |  | September 30 |
(In millions - unaudited) | 2022 |  |  | 2021 |
TOTAL ASSETS |  |  |  |  |
Life Sciences | $ | 1,940 |  |  | $ | 1,945 |
Personal Care |  | 1,114 |  |  |  | 1,145 |
Specialty Additives |  | 1,638 |  |  |  | 1,636 |
Intermediates |  | 175 |  |  |  | 160 |
Unallocated and other |  | 1,913 |  |  |  | 1,726 |
| $ | 6,780 |  |  | $ | 6,612 |
(a) Intersegment sales from Intermediates are accounted for at prices that approximate fair value. All other intersegment transfers are accounted for at cost. (b) Includes a capital project impairment of $9 million for the six months ended March 31, 2021 relating to a long-term capital project plan change at a plant facility. (c) Excludes income (loss) from discontinued operations, other net periodic benefit income (expense) and net income (loss) on divestitures. See the Statement of Consolidated Comprehensive Income (Loss) for applicable amounts excluded.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration